Lynparza stalls pancreatic cancer in patients with BRCA mutations: study
AstraZeneca and Merck& Co's Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go nearly twice as long without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial presented on Sunday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: AstraZeneca | Cancer | Cancer & Oncology | Clinical Trials | Genetics | Health | Merck | Pancreas | Pancreatic Cancer | Study